Optimal multimodal treatment for desmoplastic small round cell tumors

Olivier Mir; Julien Adam; Charles Honoré

doi:10.1001/jamaoncol.2018.2146

Optimal multimodal treatment for desmoplastic small round cell tumors

Olivier Mir, Julien Adam, Charles Honoré

Résultats de recherche: Contribution à un journal › Letter › Revue par des pairs

1 Citation (Scopus)

langue originale	Anglais
Pages (de - à)	1301
Nombre de pages	1
journal	JAMA Oncology
Volume	4
Numéro de publication	9
Les DOIs	https://doi.org/10.1001/jamaoncol.2018.2146
état	Publié - 1 sept. 2018

Accès au document

10.1001/jamaoncol.2018.2146

Autres fichiers et liens

Lien vers la publication dans Scopus

Contient cette citation

@article{5b4c8b847d9441f4b3ba3f84d5eef31e,

title = "Optimal multimodal treatment for desmoplastic small round cell tumors",

author = "Olivier Mir and Julien Adam and Charles Honor{\'e}",

note = "Funding Information: Conflict of Interest Disclosures: Dr Prasad reports receiving royalties from his book Ending Medical Reversal, that his work is funded by the Laura and John Arnold Foundation, and that he has received honoraria for Grand Rounds/ lectures from several universities, medical centers, and professional societies. Dr Mailankody is a clinical investigator on clinical trials supported by Juno Therapeutics, Janssen Oncology, and Takeda Oncology. No other disclosures are reported.",

year = "2018",

month = sep,

day = "1",

doi = "10.1001/jamaoncol.2018.2146",

language = "English",

volume = "4",

pages = "1301",

journal = "JAMA Oncology",

issn = "2374-2437",

number = "9",

}

TY - JOUR

T1 - Optimal multimodal treatment for desmoplastic small round cell tumors

AU - Mir, Olivier

AU - Adam, Julien

AU - Honoré, Charles

N1 - Funding Information: Conflict of Interest Disclosures: Dr Prasad reports receiving royalties from his book Ending Medical Reversal, that his work is funded by the Laura and John Arnold Foundation, and that he has received honoraria for Grand Rounds/ lectures from several universities, medical centers, and professional societies. Dr Mailankody is a clinical investigator on clinical trials supported by Juno Therapeutics, Janssen Oncology, and Takeda Oncology. No other disclosures are reported.

PY - 2018/9/1

Y1 - 2018/9/1

UR - http://www.scopus.com/inward/record.url?scp=85053412915&partnerID=8YFLogxK

U2 - 10.1001/jamaoncol.2018.2146

DO - 10.1001/jamaoncol.2018.2146

M3 - Letter

C2 - 30003230

AN - SCOPUS:85053412915

SN - 2374-2437

VL - 4

SP - 1301

JO - JAMA Oncology

JF - JAMA Oncology

IS - 9

ER -